Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Efficacy of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (The ANALLISA Study)

NCT06180356 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT06180356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06180356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Efficacy of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (The ANALLISA Study)
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2024
Completion date
January 31, 2028
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease, ovarian cancer, serous ovarian tumor